Good morning, everybody, and thank you for joining us today, both in person and via the webcast. On behalf of our team and our board of directors, I want to welcome you to our Investor Day 2023. My name's Anthony Fernando, President and Chief Executive Officer of Asensus Surgical. We are incredibly excited to share with you more detail about how we have evolved the way laparoscopic surgery is performed and what our vision for the future of surgery is. Before we get started, I'd like for you to refer to our forward-looking statements. For more details on these, please visit our IR website. Turning to our agenda, we will begin with a review of the surgical robotics market, followed by an in-depth discussion on how we intend to improve the way surgery is done through our vision for Performance-Guided Surgery. This will include an introduction to our next generation digital surgery platform, an overview of our recent announcement, collaboration with KARL STORZ. A deep dive into the Intelligent Surgical Unit or ISU and its capabilities, as well as a review of the Asensus Cloud, including a discussion of our recently announced collaboration with Google Cloud. We will wrap up with an overview of what you should expect to see from us in the future, including development roadmap and a list of key milestones. Following the formal presentation, we will be hosting a moderated surgeon panel. After the panel, we will open the floor to a Q&A session after which, we will shift to product demonstrations and a reception will take place in the room next door. While many of you are familiar with the Asensus story, I want to walk you through a bit of more detail who we are and what our vision for the future is. At Asensus, we are digitizing the interface between the surgeon and the patient. We are pioneering a new standard of surgery for increased control and less variability to drive consistently superior outcomes. Our currently marketed Senhance Surgical System has pioneered Digital Laparoscopy, providing surgeons with an unprecedented level of control, integrating innovative technological advances to help surgery become more instinctive, more reproducible and predictable. Since its launch, Senhance has had a unique value prop... core capabilities, including the continued push into real-time clinical intelligence, something that surgeons had previously never had access to in the operating room. We are not stopping there. We know that the future of surgery will require a holistic solution, one that combines the benefits of robotic precision with advanced intelligence capabilities to allow surgeons the ability to deliver improved outcomes consistently. Our entire global team is fully... video to highlight our global team and their efforts. Asensus Surgical is a group of trailblazers that set out to tackle some of the shortcomings of existing technology in surgery. Every individual I work with is dynamic and is an expert in what he or she does, but knows so well how to work well with others. I think that's what makes us so special as an entire collaborative team across the globe. Surgery is a highly stressful environment. Hundreds of decision need to be made on a per case basis, hundreds of surgical maneuvers. Quite frankly, surgeons don't have access to technologies that are readily available in other industries. For Asensus, the voice of the customer is very important. For this, we are always in contact with our users and users that are not only the surgeon but also the clinical staff that works in the OR to help the surgeon to be comfortable during the procedure, to feel less fatigue, and thanks to this, be more precise during the procedure. Asensus was started really with the idea that there's always going to be room for innovation in medical devices. There's always going to be complication rates that are unacceptably high. We think that there's lots of room left in the robotics market, and there's an enormous space in the digital market for concepts that could not have been brought to market five years ago or 10 years ago. They've needed the advancements in machine learning and computer vision. We can bring those together meaningfully in a way that really suits the surgeon and ultimately, of course, suits the patient. I think that the future of surgery will be robotic surgeries, will leverage the information that the robot can provide them that will decrease the amount of time that needed to be spent for each surgery while increasing the results we are getting and limiting the amount of complications that we have today. By digitizing the interface between the surgeon and the patient, we're able to reduce variability between one procedure and the next. Most importantly, the surgeon is working in a comfortable position, and the patient is able to recover faster from the procedure because the incisions are small. We are changing the operating room to improve outcomes for surgeons, to improve outcomes for patients through AI in ways that we can't even envision yet as a society, and it's exciting to be such a part of that future. I'm extremely proud of the tremendous senior leadership team, in addition to who you saw on the video, we have built globally, whose skills, experience, and expertise are unrivaled. With industry leaders across all of our global functions supported by extremely talented teams, we have the people in place throughout the organization to deliver on our vision of evolving surgery. Nearly all of our senior team on this slide are in this room today and available to interact with you after the presentation. In addition, I'm pleased to introduce you to two of our Board Members who are here also, our Chairman, David Milne, and Board Member, Andrea Biffi, whose company was the original architect of the Senhance system. You know, with that background on who Asensus is, we can now turn to the purpose of today's event to walk you through how we plan to transform the surgical landscape. Where do we sit today? We've made considerable inroads with the development and commercialization of the world's first and only digital laparoscopy platform, which we call Senhance. We have successfully taken the platform through the regulatory process in most of the world's largest robotics markets, including the U.S. and Japan. We have also completed the European Union's new MDR process, and we are fully cleared there as well. We remain just one of two companies in the world with an FDA-cleared multi-port soft tissue robotic surgical platform. We have created a commercial model for hospitals that allow them to realize the benefits of digital laparoscopy with per-procedure costs that are in line with traditional laparoscopy. We believe that delivering this economic value proposition will continue to be critical to driving widespread adoption. To date, over 10,000 procedures have been performed with the system across multiple continents and across a wide variety of surgical specialties. We have grown our surgeon user base to over 100, who operate in different geographies throughout the U.S., Europe, and in Asia. Throughout that journey, we have maintained an excellent safety profile with virtually no complications or system-driven adverse events reported. We also have a growing repository of clinical data as part of our TRUST registry, which remains the largest registry of its kind. What we know now to be true as a result of this extensive real-world clinical and commercial experience working alongside surgeons and hospitals, is that we have what it takes to pioneer the future of surgery, and that we are on the right path with our Performance-Guided Surgery vision. With the growing adoption of the Senhance system, and more recently the ISU, we know that the types of advanced clinical technology we are developing for surgeons is resonating. We have a deep knowledge and understanding of the clinical and regulatory landscape and have established trusted relationships with regulatory bodies globally, which is a key competitive advantage for us in the robotics market. We have an understanding of the commercial landscape as a result of our expanded adoption of Senhance to a growing number of hospitals across the globe over the last few years. Taken in combination with what you will hear today about the advanced technology we are developing, our outlook on the future of this company has never been so exciting. You heard our thoughts. We wanted to share the perspective from people who actually use our technology, the surgeons. A few years ago, when I became chair of surgery at Pascack Valley Medical Center, I knew that the future of surgery was going to involve robotics. We all know that cost in healthcare is a big barrier, whether the hospital can afford technology or not. That all can change in the near future through companies like Asensus. There are so many things that can be done with this system, and because it's based on laparoscopy, it's easy to train other surgeons with minimal learning curve. Asensus were the first to design the open console. Surgeon being at the operating table, sitting with his 3D glasses, and looking at the screen, and having this magnificent 3D view on operating field he's working on. At the same time, he can always have a look at the operating table. He can always know what's happening there, what the assistant is doing, what the scrub nurse is doing. With Smart Tracking, wherever my retina moves on the operative field, the camera follows. That's amazing. You're more precise. You know, you can see the structures better. You have a haptic feedback. Other systems do not have it. I think I'm better when I'm working from the console for all these reasons, for better view, for stable view, for 3D vision, for haptic sensation. I feel less exhausted. Obviously, if the surgeon is less tired, his quality becomes better. Many studies have been published to show benefits for the patients with robotic surgery. I think that we also have to focus on surgeons' issues such as ergonomics and peace of mind. We are facing a shortage of active surgeons. The future of robotic surgery goes far beyond patients' needs. It will be one cornerstone to keep future surgeons in the game for the rest of their professional life. Two of these surgeons are in the room here today. You will hear from them more later on. To provide a deeper dive into the trends we are seeing in the surgical market and to share our learnings that underpin the development of our future technology, I would like to invite Ethan Loiselle to the stage. Thanks, Anthony. As Anthony mentioned, my name is Ethan Loiselle, and I am the Vice President of Global Marketing here at Asensus, and I'm awfully happy to have joined the team last year. One of the things that I've learned in I guess my 25 or so year career in medical device and consumer marketing is that when you combine a great product with probably an even better team, you get to have a great solution and have a lot of fun from a marketing perspective delivering it. Hopefully you'll get to see that today as we go throughout the day. Anthony used the term digital laparoscopy a number of times in the last few minutes. This is because we see laparoscopic or minimally invasive surgery as the gold standard for patient outcomes. Simply put, patients that have their procedure performed laparoscopically have better outcomes than if their surgery was done open. The same time, while robotic surgery has been in the market for over 20 years, outcomes for robotic procedures remain similar to that of lap, not better. Leading to an adoption that's only been about the mid-single digits. A focus on surgical variability, we at Asensus believe that there are some good reasons for this low adoption. The primary of which is that lap and robotics focused on the invasiveness of procedures through the visualization systems and the instruments to make procedures less invasive. This improved areas like incision site pain and patient length of stay. Surgical variability remained, and issues like procedural complications remained highly dependent on the skill and experience of the surgical team. To further improve these outcomes, variability needs to be reduced. To do this, the next set of digital solutions are needed. In the next couple of minutes, I'm going to share our perspective on both the overall surgical market as well as our learnings from the over 10,000 procedures performed using the current Senhance system. As we look at the market, I mentioned since its introduction in the early nineties, lap procedures have helped patients to often leave the hospital faster with quicker overall recovery, leading to benefits such as reduced pain versus their open surgery predicates. Yet even with these improvements for patients, of the millions of surgical procedures performed globally, lap procedures make up less than half of those performed. While some markets like that of Japan have surpassed this 50% mark, most of the markets have not. This is due in part to the complexity and the physical demands that these procedures place on the actual surgeon. Let's talk about the robotic surgery market. Despite all of the emphasis on robotics as an enabling technology, its penetration remains low, accounting for just about 6% of all procedures performed globally. This has improved the overall MAS adoption to just around 50%. There's a lot of room for market penetration going forward. There are a couple of reasons why robotics hasn't yet delivered the value to drive widespread adoption. Importantly, most robotic systems are expensive and materially increase the per procedure cost for the hospital. Furthermore, they've added complexity to surgery without driving significant improvements in the clinical outcomes for the patient. Let's transition to talk about why robotics has not driven the adoption that people have expected. An important factor is variability and the fact that there's a lot more work to be done to reduce this in the operating room. This variability leads to inconsistent patient outcomes, often measured through surgical complications, as well as OR inefficiencies, both of which contribute to a high financial burden for the hospital. There are several aspects to variability that we consider. One is that it impacts a lot of patients. Studies show that up to one in five patients experience a complication during their procedure. That's up to 20% of patients. Next is that it can be a function of experience measured through the volume of procedures performed by the surgical team. There are several studies that discuss how increased procedural volume by either the surgeon or the institution results in lower complication rates for patients. It's also important to recognize that variability, again, measured in complications, differs by procedure and surgeons performing a surgical instrument. Surgeons and the hospital want more. They want intraoperative support for the hundreds of decisions that they make in every case every day. They also want us to understand that their productivity and frankly, their longevity is important to them. Collaboration and interaction in the OR is very important. The surgeon needs to interact with the surgical staff around them, and the surgical staff needs to interact back. Everybody wants systems that are easier to learn, and even automation of key or simple tasks are most important needs by key constituent: the patient, the surgeon, the OR staff, and the hospital. For patients, and really for everybody, they want predictable outcomes, fast recovery, and ultimately a return to normal. In order for this to happen, they depend largely on the rest that I'm gonna talk about. Surgeons, they require complete portfolio, and they do like the precision that robotics brings to them. Beyond the robot, they want more support in decisions that they make, leveraging digital tools to get real-time insights during the surgery. They also wanna be connected and have line of sight to the OR and to the patient, and they want Asensus to not forget that operating is hard. Making ergonomic tools that they can use are very important. The OR staff, this group needs to manage the room and the patient, so efficient room setup and fast instrument exchange are key. They also need to be able to access the patient and interact easily with the surgeon and each other. Finally, for the hospital, lower cost and lower complications are both very important. They also have asked for some measure of performance metrics to enable surgery to continually improve. Finally, standardization of both procedures and tools helps the hospital achieve their overall efficiency goals. With a solid understanding of the market, combined with what we've learned through observing and interacting in the OR, our charge is to meet these needs. For this, I'd now like to turn it back over to Anthony to discuss our vision for how we change the current market dynamics to reduce variability and make outcomes a reality for patients and the healthcare system. Anthony? Thank you, Ethan. We know what surgery was in the past. Ethan talked about how laparoscopy reduced invasiveness, which drove significantly better outcomes. However, the introduction of robotics did not have that same level of positive impact for patients. This is where we are today. At Asensus, we believe that better surgery requires an integrated solution consisting of the best tools, both robots and instruments, the best real-time clinical intelligence, and access to data to drive pre-op and post-op clinical learnings. Since that time we began to commercialize Senhance, we have taken a number of steps to realize this vision and offer a complete digital solution, not just a robot. We made tremendous progress by incorporating various advanced digital capabilities into Senhance, including the image analytics technologies we acquired from MST in Israel. Our aspiration, however, is to bring what we call Performance-Guided Surgery to surgeons, providers, and patients. A laparoscopic camera, intraoperative clinical guidance, real-time data delivered to the surgeon at the speed of thought, and the integration of cloud big data to harness best practices from everywhere and make it available to any surgeon anywhere. Over the remainder of the presentation, we will walk you through our strategy for developing industry leading capabilities with each of these areas and how we plan to combine them together to create the most advanced. With that, I'm super excited to share with you the LUNA Surgical System, the digital surgery system of the future. As I mentioned before, we are incredibly excited to walk you through our next generation platform that we call LUNA. To do so, I would like to introduce Dustin Vaughan to tell you about it. Thanks, Anthony. My name's Dustin Vaughan. I head up our robotics R&D efforts here at Asensus Surgical. I have spent my career developing safety-critical systems for the medical device industry as well as aerospace. More importantly, I'm fortunate to lead our world-class team of over 70 full-time individuals spread across our global R&D locations in North Carolina, Israel, and in Italy. I'd like to start with an introduction to LUNA. A number of familiar elements comprise the system: the surgeon console, up to 4 independent robotic manipulator arms, and a full suite of straight and wristed instruments. In our conversations with surgeons and administrators, we consistently hear that a great robotics program hinges on precision, control, dexterity, and accessibility. To put it simply, great robotics still rules the day. The foundations of the LUNA Surgical System deliver on these core needs, enabling surgeons across multiple specialties to perform at their collective best. We have collected considerable clinical feedback and commercial feedback from the growing Senhance global install base and the over 10,000 procedures completed using the system, and incorporated those learnings into our next generation system. The hardware and software architecture of LUNA was carefully selected based on our deep understanding of the needs of the surgeon to ensure safety, reliability, performance, and scalability to support continuous enhancements for the next decade. We have been developing LUNA for nearly four years and believe it will outperform all other robotic-assisted surgery platforms on the market, both now and in the future. We didn't start this process by immediately cutting material in our in-house machine shop. We leveraged our firsthand clinical experience and global relationships with surgeons, OR teams, strategic partners, as well as hospital administration to begin the development process. LUNA evolved through our understanding of the limitations of the currently available systems and the required performance criteria for the soft tissue surgical field in the coming years. Our efforts through countless simulations, user studies, multiple engineering iterations, and continuous refinement have led us to today's unveiling. These iterations and refinements have afforded the team the opportunity to prepare the system for manufacturability and scaling, even in the midst of continued global supply chain challenges. This design for manufacturability and design for assembly process has been supported by a deep bench of engineering talent. Internally, as well as through our contract manufacturing partners, all of whom have experience and a track record of success in the medical device industry. Importantly, the system was purpose-built throughout its various design stages to effectively and efficiently comply with global regulatory approval processes. Simply building a robot is one thing, and as you are all well aware, many companies are working to accomplish this goal. However, we understand what is required to achieve approvals across the world's largest markets, and we have designed LUNA to do so. We have been there, and we have done that successfully. Let's start first with the console. In a future with unmanned aircraft, rich virtual reality experiences, and computer vision, why are surgeons still manipulating complicated mechanisms and linkages? The LUNA console eliminates all of those complexities and provides the surgeons with unmatched freedom of movement. The console introduces the first digital interface using multiple sensing modalities and algorithmic sensor fusion. We are sensing the position and the velocity of the surgeon's hands up to 10,000 times per second with a resolution below half a millimeter. These sensors are a combination of those already used in medical devices, as well as proprietary technology, which we believe will give us a protected IP position for years to come. With our unconstrained handles, the ergonomic surgeon's workspace becomes home to an interactive touchscreen to access LUNA's unique portfolio of digital tools. Live measurements and annotations are just the beginning. Our strong roadmap for digital solutions will deliver clinically relevant, evidence-supported, and value-adding tools for years to come. In addition to LUNA's unconstrained handle interface, we have selected an ultra HD 3D monitor that does not require the user to wear glasses. This particular technology leverages an active eye tracker, which we have long relied on in our Senhance platform for camera control. The monitor dynamically tracks the surgeon's eyes to ensure the 3D image shown is clear, crisp, and comfortable throughout their usual head movement while seated at the console. This novel display will be used with the industry's only 4K 3D laparoscope from endoscopy leader KARL STORZ. Our years of experience with force feedback on Senhance has given us insight into what matters most to surgeons. Freedom of movement isn't enough without the ability to feel patient anatomy. That's why we're delivering critical sensory feedback to the platform that enables OR efficiency and high utilization to hospitals is to limit the disruption to existing workflows. We have reduced the footprint of the arm by over 30% while providing considerably more range of motion. In addition, the arm is specifically designed to be easy to set up and simple to use while delivering high performance to the surgeon. The multi-arm system allows for procedural flexibility. Onboard sensors detect the position of each arm to provide guidance and enable seamless preoperative equipment setup by the surgical staff. Preoperative guidance is critical to expedite room setup and provide surgeons and OR staff confidence in the procedure they are tackling. For example, for a given procedure and a known patient BMI, the system will provide a recommendation for the most optimum system setup to the OR team, which updates in real time as the robotic arms are moved into position. Let's continue with our instrument drive system. This is effectively a five degree of freedom robot attached to the end of our seven degree of freedom manipulator arm to provide exceptional access and flexibility. This is where the instrument is detected, secured, and manipulated. 4 precise carriages drive the instrument with independent dynamic tension management. Single-handed instrument exchange ensures the highest possible safety and efficiency for the bedside staff. The drive system was designed to support the needs of the surgeon with respect to advanced instrumentation, such as energy and stapling, to allow the surgeon to remain seated at the console for the duration of a variety of procedures. The LUNA Arm utilizes a patent-protected virtual fulcrum to sense and monitor for forces at the incision site and enable the use of off-the-shelf trocars. This virtual fulcrum feature has consistently been one of the customer delights of our Senhance system, and we are pleased to continue improving on this advanced functionality with the LUNA platform. With our IP portfolio, we are in a unique position relative to other players in the space where we can actively provide a managed virtual fulcrum, which we believe will continue to materially reduce incision site trauma while making system setup more efficient. When we talk about designing a platform from the ground up for the next generation of robotics, it's not just industry jargon. We are using the latest frameworks and toolsets which provide us with comprehensive development and simulation tools and offer exceptionally low latency. With this approach, we've been able to holistically optimize the robotic system to deliver best in class response time, velocity, and linear dexterity. We have arrived at this design after evaluating all of the competitors in our market and through our virtual fulcrum, unrivaled range of motion, and broad workspace dexterity, we believe we have achieved a manipulator with performance capabilities that will not be matched in the market. Yes, we feel we've taken the right steps towards securing the IP needed to bring this device to market. We have a strong robotic platform with leading technology, force sensing, haptic feedback, proprietary digital handles, less obtrusive arms that preserve critical access to the patient and the sterile field, and robust preoperative guidance. It's still not enough. Surgeons are looking for evolution in robotics. Surgeons want all of the dexterity they've become accustomed to in robotics. They want less invasive options. How do you reduce the instrument diameter without sacrificing performance? The LUNA system and instruments solve these challenging problems and dichotomies by deploying advanced technologies to the OR. At the end of the day, there's one part of the robot doing the work, and that's the instrument. No robot can be better than its instruments. Introducing the LUNA TrueWrist family of instruments. The TrueWrist instruments are a remarkable 5 MM in diameter. By area, these instruments are 43% less invasive than traditional 8 MM instruments, allowing for unparalleled access and approach, and yet there's no sacrifice in performance. These instruments have all of the grip strength, jaw patterns, and monopolar and bipolar electrosurgery capabilities that surgeons expect. Critically, these instruments support the use of off-the-shelf standard 5 MM trocars, which enables hospitals to continue utilizing preferred vendors and workflows within their broad laparoscopic suite. We have developed these instruments to provide the same level of performance over their life, which meets or exceeds industry standards for the number of cases performed per instrument, thus lowering operational costs for providers. At Asensus, we focus on our strengths in robotics and digital tools, we have been fortunate to leverage other leading industry players to develop instruments and visualization devices. The TrueWrist instruments have been in development for many years, we have IP surrounding the novel elements of the design. However, the instrument line needed a world-class instrument maker to realize the design and vision at scale. I am pleased to announce that in addition to integrating their vision platform and supplying both three and 5 MM straight instruments, KARL STORZ will be supporting the development and manufacture of the TrueWrist instruments for the LUNA platform. Bringing it all together, we believe LUNA will transform the robotic-assisted surgery market and attain a leadership position in the space. As a direct result of our development efforts focused on the full surgical value chain, we will deliver meaningful solutions for surgeons, OR teams, patients, and hospitals. We will continue to offer the surgeon novel camera control modalities, an open console for improved communication and ergonomics, haptic feedback, a comprehensive suite of advanced instrumentation to enable complex procedures across a broad range of specialties, and a first of its kind fully digital console environment. The OR team will benefit from LUNA's design simplicity, approachability, efficiency offered by our preoperative system setup, off-the-shelf three and 5 MM trocars, rapid and secure single-handed instrument exchanges. Patients have long benefited from the gold standard of laparoscopy, and we are delighted to offer the return to the industry expected 5 MM diameter instruments with the TrueWrist instrument line. The combination of 3 MM instruments, fully wristed and highly dexterous 5 MM instruments, and our virtual fulcrum will offer patients the least invasive robotic surgical offering available globally. As Ethan mentioned, healthcare institutions and administrators continue to see costs rise, and it has impacted the adoption of robotic surgery. Together with our industry partners, we will produce instruments and other consumables at scale to ensure we continue to deliver on our promise of responsible economics. Thank you all. I'll turn things back to Anthony. Thank you very much, Dustin. We are really excited about the LUNA platform and the state-of-the-art technology behind it. Before we turn our conversation to accelerating digital capability development, we wanted to provide a deeper dive into the recently announced KARL STORZ collaboration. To provide this overview, I'd like to invite Stephan Abele to the stage from KARL STORZ. Thank you very much, Anthony. Good afternoon, everyone. My name is Stephan Abele. I'm the Managing Director of KARL STORZ VentureONE, and it's a pleasure for me to be here to speaking to you today. I would like to share with you a little bit about our company, who we are, and why we believe that this planned collaboration between us and Asensus is beneficial for both parties. It's not moving. Here. Sorry. For those of you who may not be familiar with our company, Karl Storz was founded in 1945 in Tuttlingen, Germany, and is an international leader in the world of endoscopy. Now in its third generation, the family-owned company employs 8,300 people at 70 locations in 40 countries worldwide. The company's portfolio includes more than 15,000 products for human and veterinary medicine. KARL STORZ stands for visionary design, precision craftsmanship, and clinical effectiveness. Our sales for the fiscal year of 2021 amounted to nearly EUR 2 billion. You see from this slide, we have a significant global infrastructure. We are highly focused on bringing new technologies to all patients, regardless where they reside. We do this either through our direct sales teams in more than 40 countries or through our many channel partners in the rest of the world. We are excited about the potential of adding Asensus leading surgical technologies into our distribution network, allowing for more hospitals, surgeons, and patients to benefit from these technologies on a daily basis. We also have a global world-class manufacturing facilities with production sites located in Germany, the U.S., Switzerland, and Estonia. As a company, we have been well-known in the market for a long time, especially in integrated operating rooms, endoscopic visualization systems. Our industry-leading OR1 System is currently in use in over 10,000 operating rooms, giving us a market share of around 20% in the U.S. and the E.U. This system provides centralized control of the medical equipment and OR functions and integrates the OR into the hospital's IT infrastructure. OR1 is enhanced by the Senhance software platform, which supports the pre, intra, and post-operative processes and provides simple, safe access to endoscopic videos. Optimal imaging makes the difference in robotic surgery. Based on our long-standing experience with endoscopy, we have become an industry leader in visualization system, we currently have a significant number of systems installed globally, which represents around 28% of market share. Let me briefly introduce VentureOne to you. We are a recently created subsidiary of KARL STORZ that is headquartered in Singapore and has a second location in Munich, Germany. Our focus is on robotic solution, artificial intelligence, and virtual reality, leveraging on the expertise and technologies of KARL STORZ. We are pursuing the vision of developing a complete robotic ecosystem that is geared to the needs and requirements of our customers. Our team is committed to serve the next generation of surgeons who have grown up in the digital age. This planned collaboration with Asensus is the first agreement we have structured. We originally got to know Asensus as we began discussing how we could work together to develop and manufacture next-generation instruments for the company's robotic system. As we continued our discussions, we found that we had a shared vision for what digital surgery can be in the future and expanded our discussions to integrate the ISU into our OR1 and visualization systems. We also share a common culture, as both organizations have a unique cutting-edge R&D group in the forefront of their fields, and our organizations will be leveraging those groups to deliver best-in-class instruments, technologies, and solutions to surgeons to enable them to drive the best possible patient outcomes. We are excited about the potential of working with Asensus going forward and look forward to seeing our collaboration develop. Thanks, Anthony, and I will turn the podium back to you. Thank you. Well, thank you, Stephan. We are really excited about what we intend to create together in the near future for surgeons and patients globally. In the next 90 days, our teams will be working together to finalize the definitive agreement. There are three key areas where we are excited to collaborate with KARL STORZ VentureONE. First is, first there's like, there's a commercialization component in which KARL STORZ will sell a standalone version of the ISU together with their industry-leading imaging solutions by leveraging the KARL STORZ extensive commercial network, their leading visualization system and long history with instrumentation expertise. We believe we can bring tremendous value of Augmented Intelligence offered by the ISU to operating rooms around the world, separate and apart from the value that ISU will deliver with the LUNA system. Second, there's an integration component in which the companies will work together to integrate the ISU into their laparoscopic vision systems. Finally, there's an R&D component in which the co-companies will work together to design next-generation instrumentation to be used with the Asensus LUNA surgical platform. Combining two unique R&D teams at the forefront of their fields to ultimately deliver best-in-class instruments to surgeons. We too are excited to see our collaboration grow in the future. As Dustin shared earlier, our ability to deliver precise robotic manipulation has been well established and will continue to advance our instrument portfolio with the KARL STORZ collaboration. Now I would like to discuss the ISU, our platform for delivering real-time intraoperative clinical guidance and the piece of equipment that KARL STORZ will sell and integrate into their platform. With that, I would like to introduce Motti Frimer, who was the CEO of MST, the company that we acquired in 2018, which forms the foundation of our digital platform. Thank you, Anthony. My name is Motti Frimer, and I'm the vice president of R&D for Digital Solutions and managing director of Asensus Israel. Throughout my 20-plus years of technology and leadership experience in high tech, defense, and medical technologies, I am truly excited to be here. At Asensus, we are pioneering the introduction of Augmented Intelligence to redefine soft tissue minimally invasive surgery. Our goal is to provide surgeons with the information that enhances, not replaces, their decision-making. Let's begin with a few definitions. Artificial intelligence refers to the ability of machines to do things that usually requires human cognition, such as learning, problem-solving, and decision-making. Augmented intelligence is the use of that technology to enhance human intelligence rather than replacing it. It does so by improving human decision-making and by extension, action-taking in response to improved decisions. When we at Asensus apply augmented intelligent technologies to the surgical space, we call it intraoperative clinical intelligence. We define this as the ability to perceive, learn, and assist surgeons in optimizing workflows and enabling higher levels of accuracy and precision by serving as a digital assistant or copilot. The future of intraoperative clinical intelligence is being delivered through the Intelligent Surgical Unit or the ISU. I will now walk you through the ISU current capabilities as well where we plan to take the ISU in the future. By using the most advanced technologies in computer vision, machine learning, and data analytics, the ISU captures and analyzes laparoscopic video feeds during surgery, as well as previously collected data. Accordingly, the ISU provides actionable real-time information to surgeons when it matter most during the actual surgical procedure. This real-time information is fully incorporated into the surgical video being seen by the surgeons and dynamically interacts with surgical actions, tool movements, and scene changes. This isn't the future. This technology is globally available, and it's currently being used on a daily basis as part of our Senhance Surgical System. The ISU is a custom-designed, high-end medical computer that runs within the operating room during surgery and integrates with the surgeon vision system. In real-time, it manages several data feeds control and including the laparoscope video feeds, the robotic platform management, console displays, and more. It optimizes those inputs to reduce all sources of lag and provide high processing computing resources that are needed. A key element of the ISU is the connectivity to the cloud. While the ISU is utilized intraoperatively, it is also connected to the Asensus Cloud. The ISU captured huge amount of data that are generated during surgery. Prior to the launch of the Asensus Cloud, this data wasn't being collected efficiently nor in the quality needed. As Brian will discuss in detail, this data is then organized, anonymized, and providing a wealth of information we can use to feed our machine learning engines, allowing us to develop new intelligence capabilities and features in order to solve more complex surgical problems. Let's look at some of the ISU features that are currently available and being used across the globe. Starting with camera control. When the surgeon turns on the camera control options, neither the surgeon nor their assistants need to manage the camera, freeing surgical assistant to attend to other tasks within the sterile field. An indication of surgical experience is the ability to balance operative task demands with available cognitive resources. Surgeons sometimes experience a state of cognitive overload that can impair performance during specific tasks. Advanced camera control has been shown to reduce cognitive load and enable greater focus during surgery, improving patient safety and operating experience. The second feature we want to highlight is digital tagging. Prior to the introduction of the ISU, surgeon communicated about various surgical and anatomical structure by pointing at an image on the screen. With the ISU, we offer the ability to annotate the anatomy easily. Those annotations are presented in 3D space with real-time stickiness to the tissue. The digital tagging feature enhances the ability to provide visual instructions, allowing surgical teams and specialists to collaborate more efficiently. Turning to digital measurements. Today, surgeons often use pre-op data for medical imaging, such as ultrasound, and then incorporate this information intraoperatively. In addition, surgeons also sometimes use surgical ruler, which are similar to the tape measures, to measure distances within anatomical structure with the patient during the operation. Using the ISU, surgeon can accurately and seamlessly measure anatomical structure between two points during the procedure. This ensure procedural repeatability and provides meaningful metrics to support real-time decision-making. Accurate distance measurement at the point of care helps to improve procedure efficiency, ensure successful outcome, and reduce variability. What we have just reviewed are the fundamental elements of the ISU and its core Augmented Intelligence that are currently exist and are being used in surgery today. Where do we go from here? We have a tremendous opportunity to continue to advance the information being provided to surgeons in operation room to address real needs. Going forward, we will focus on two areas of development for the ISU. First, adding new features to the surgeon toolbox will provide a deeper level of guidance, safety, and insight, all highly tailored to specific procedures. We are focusing specifically on three priority areas: real-time analytical tools, safety tools, and training tools. Second, as Brian will discuss more about later, based on past surgery data and current procedure information, we will provide the surgeon with real-time insight and recommendations. We'll take you through a few examples of the types of application that we, along with our external development partners, are in the process of making a reality. Our first example here is of the analytical feature set. Precise planning is essential in surgeries like sleeve gastrectomy, in which there is a need to remove a portion of the stomach for weight loss. Currently, surgeons plan the staple line during the surgery based on experience, sometimes using markers to guide the location of the final staple line. We are focused on providing the tools for the surgeon to plan out the procedure intraoperatively in real-time. This will assist the surgeon in removing the correct portions and shaping of the remaining section correctly for proper function. It will also allow the surgeon to guide the staple line for optimal outcome. The measurement capability is also further enhanced to provide more information, such as plane measurement for reference. The next example is of our safety feature set. Currently, in order to perform a surgery safely and accurately, surgeons use their anatomical knowledge and surgical experience to avoid damaging critical structure. Our clinical intelligence guidance, along with the surgeon input, will enable the identification and making of an area that may pose a risk. This capability will enhance situational awareness near critical structures and may reduce cognitive load and complications. The last example is of our training and education feature set. In minimally invasive soft tissue surgery, surgeons collaborate as a team to ensure successful outcomes. Communication is done mostly through verbal or non-verbal hand gestures, pointing tools, and other means in order to coordinate actions for a successful outcome. By utilizing collaborate augmentation tools like the displayed illustration features, multiple team members can work together in real-time by annotating, highlighting, and drawing on a shared visual display. As a result of this capability, team communication and decision-making will improve, and real-time consultation and proctoring will be possible. Hopefully, these examples have demonstrated the power of real-time intraoperative clinical intelligence in surgery and the opportunity that we have to assist surgeons in delivering better outcomes. I would like now to turn on the presentation back to Anthony. Thank you. Thank you, Motti. As you just heard, the ISU with Augmented Intelligence is a novel technology that brings highly sought-after clinical decision support to surgeons in real time when they need it most during surgery. This support will help enable surgeons to be more efficient, save time, and reduce costs, helping to eliminate accidental errors and improve overall patient safety, and will help surgeons make the most effective decision all in real time during the procedure. Ultimately, the ISU will enable consistently better surgery, resulting in improved outcomes and reduced costs to the healthcare system. I would now like to shift gears from the intraoperative technology deployment and surgery applications to another key differentiator for us and the third pillar of the Asensus Cloud. This is a key enabler for the development of both our current and future Augmented Intelligence applications, also ensures our ability to scale and expand our analytics capabilities across all customer types. Before I turn the podium over to Brian, let me give you a sense of how the ISU and the Asensus Cloud work together to drive clinical intelligence. As Motti indicated, the ISU collects an enormous amount of data during a surgery, including what the surgeon was doing and how the robot was used. In addition, the video of the entire surgery is captured. This data is uploaded to the Asensus Cloud, where it is processed to allow for future analysis and learnings. This data is analyzed to provide surgeons and hospitals with procedural insights and aggregated to drive clinical learnings. To further go on the Asensus Cloud, I want to introduce Brian Stellmach. Thank you, Anthony, and good afternoon, everyone. My name is Brian Stellmach. I'm the Vice President of Digital Solutions here at Asensus. I joined Asensus after spending the previous about 15 or so years in the medical device space in a variety of marketing, strategy, innovation, business development, M&A, and leadership roles. I just have to say it's been an absolute thrill to join such a talented team. I'm excited to be with you here today to spend a little bit of time talking about the power of the Asensus Cloud, where I'll be focusing in on some of the most unique aspects of the cloud, as well as some of the challenges that we believe we'll be able to overcome to make the most out of surgical data across the pre, intra, and post-operative settings. Some of the challenges and opportunities that I'll touch on are related to the sheer volume of data that we're talking about, as well as some of the unstructured nature of surgical data as it exists today. In particular, we'll talk about providing structure via the cloud and introduce our idea of democratizing surgical data annotation, which will help us with some of the more manual aspects of machine learning model development. All this in an effort to continuously improve surgical outcomes by leveraging data. Let's dive in. We'll start off with the ISU. As Anthony mentioned, our augmented intelligence engines are what allows the ISU to deliver intraoperative real-time clinical intelligence. The better, faster, and more sophisticated we can make these machine learning models, the better, faster, and more sophisticated we can make the outputs to help surgeons perform superior surgeries. Our ability to capture, transform, and then leverage the surgical data for these models is what will enable the future of surgery. This is gonna require a little bit of a shift. In the recent past, there was nearly zero digital data that was being captured out of the OR. Today, we're doing a better job of accumulating the data. However, it still tends to be infrequently captured and unstructured when it is, often in random video segments and potentially a couple of still images captured in different file types. As we move into the future, we're working toward a state where massive amounts of data can actively be collected, processed in the highest quality, and then delivered into a database where it can be pooled for a number of different uses. Before we get too far into the future, let's answer the question: What data are we as Asensus collecting today to enable that future? To be clear, we do not collect any patient information data. What we do collect are primarily intra-abdominal images as well as robotic data. This includes large laparoscopic video files along with robotic telemetry, kinematics, as well as log files. This essentially enables us to digitally reproduce an entire surgery step by step, move by move to analyze and optimize in the future. This is a critical foundation for us to build upon with digital surgery moving forward. Once this data is collected via the ISU and automatically pushed into the Asensus Cloud, it's then processed and organized, so we can manipulate it and optimize it for use in two very different but important ways. The first one is intraoperatively with our Augmented Intelligence applications. The second is for new analytics engines that we'll dive into. In the first case, Augmented Intelligence development, the normalized data is fed into our training and validation models for our machine learning models that enable the Augmented Intelligence that Motti just spoke about. For number 2, the new analytics engines, that same data is allowing us to push beyond the OR and add real value in both the preoperative planning and the postoperative evaluation settings by providing actionable insights. One point to highlight here is that data is critical for sure, but so is cloud design, and all clouds are not created equal. While most players in our space have a cloud today, our team of experts has developed the proprietary Asensus Cloud, architected from the ground up with Google on their Google Cloud Platform or GCP infrastructure. Together, we've optimized the Asensus Cloud for specific applications addressing intraoperative surgical data, including considerations like you see here. The first one is, as mentioned earlier, we're managing huge video files. These are high frame rate, 4K, often in dual stream to create 3D images. We do all this without the normal compression approaches because compression can introduce artifacts, and artifacts can negatively impact our machine learning models. That's a big challenge to overcome. Some other considerations include anonymization for global data privacy regulations, as well as security by design to address cybersecurity concerns. Finally, we include adaptive scalability in multiple different domains, including storage, compute, and other things like front-end informatics. Our cloud design also includes and enables data automation, which provides significant benefits. Just one example of this benefit is for our efficient machine learning operations. Annotating individual frames of these large videos with tags and labels usually requires a certain level of clinical expertise as well as a significant amount of time. Our built-in cloud interfaces help us do what we call democratized surgical data annotation by tapping into expert clinical networks around the world who can easily and cost-effectively access, annotate on a single platform any time of day or night, which ultimately means that we're gonna be able to produce better models more quickly. Other benefits of data automation and integrations include enrichment of our databases with other big data sources, like publicly available surgical video sets or various other repositories of clinical information. The design and interfaces also ensure availability of third-party integration applications as we expand our need to scale and increase our use cases. That's a little bit about the cloud structure. If we move back to the data that's in the cloud. Once the data is collected, organized, the next critical step is for us to add intelligence to deliver value across the intraoperative and analytics for the pre and postoperative settings. Motti spoke about the exciting future of intraoperative Augmented Intelligence capabilities. We believe that our ability to efficiently collect, democratize annotations, and apply this data via the cloud, combined with our understanding of real-world surgical needs, will enable an extensive pipeline of more and more complex and more and more valuable augmented offerings well into the future. Separately, that same cloud data also enables powerful statistics and analytics to address challenges in the pre and postoperative setting. Data informatics delivered via customer portals and dashboards are just some of the examples of how we can leverage this data to create new customer value. To illustrate, I have a couple of examples here. You can imagine a surgeon at the end of a long day opens up their laptop and uses a dashboard function to review their recent cases, postoperatively visualizing their own performance, maybe some changes over time, procedure types, et cetera. In a different case, a surgeon might be faced with a particularly challenging complex case where they pre-operatively search their own history for a similar case that they did years ago on their tablet. They can review the video and apply some of those learnings to the new case at hand. Another dashboard could pool data types for an OR manager to compare procedure time, times to national averages or global averages, also looking at trends. We can basically provide customized analytics to various customer types, including surgeons, administration, research teams, and more. We plan to offer a number of these analytic solutions in the very near future, leveraging the data from the ISU across our global install base. In addition, through our relationship with KARL STORZ, we'll have access to an even larger volume of data from their laparoscopic towers, as well as the integrated OR systems. With this large and growing volume of data, the variety of options and iterations for our analytic solutions should advance quickly, accelerated, since these updates we make to the software do not require the separate regulatory approvals. Importantly, with these solutions, while we could do almost anything, we'll be focused initially on addressing some significant well-known customer needs, including surgical variability. Ethan talked about this challenge earlier. You can imagine with the datasets that we're talking about, how statistics may be helpful to identify sources and/or correlating factors that otherwise would remain hidden. Once these are identified, we could basically research, change these and at the end of the day, improve outcomes by leveraging these statistics. We also believe that additional applications exist for statistics and analytics addressing other macro challenges, like surgeon shortages, inefficiencies with things like preoperative scheduling, addressing disposable product waste, among other things. At this point, hopefully you can see how the Asensus Cloud is uniquely positioned to help surgeons and patients, facilitating both intraoperative Augmented Intelligence portfolio development, as well as insightful analytic solutions in the pre and postoperative setting. Okay. I'll conclude by noting that we're very excited about our plans to leverage and expand our cloud capabilities in the near future, and that we're extremely confident in our ability to execute, not only because of the amazing teams that we have assembled internally or because of the technology that they've already implemented to date, but also because of our collaborations we've established with global technology leaders. As announced last week, we look forward to expanding our collaborations with Google to further integrate Google Cloud's secure cloud data architecture and machine learning technologies to further enhance the Asensus Cloud capabilities. This will enable us to more efficiently and effectively deliver solutions across the surgical continuum and also support our ability to scale. This is important since we plan to quickly increase our install base and accelerate our pace of digital innovation in order to address the needs of surgeons and patients involved in the tens and millions of robotic and laparoscopic surgeries done every year, thus delivering on the promise of improved surgery through data. Thank you. With that, I'll hand it back over to Anthony. Thank you, Brian. Hopefully, you know, we have given you a clear sense of the three key components of our digital surgery solution. Bringing together the most advanced robotic manipulation platform and instruments with LUNA, first of its kind intraoperative clinical guidance with ISU and integration with the Asensus Cloud. We will be able to realize our vision for Performance-Guided Surgery. You know, Performance-Guided Surgery is surgery reimagined. By executing our vision, we can enable better surgery by reducing surgical variability and deliver benefits to all key stakeholders involved, patients, surgeons, OR teams, and the hospital. Let me now give you a roadmap of how we will get there. Beginning with the LUNA program milestones on the top of the slide. With much of the R&D efforts having been completed over the last few years, we will be quickly moving into testing and evaluation ahead of regulatory filings. During the second half of 2023, we will have surgeons perform system tests to provide feedback before completing preclinical evaluations of the fully built system by the end of the year. During the first half of 2024, we will freeze the system's design, complete verification and validation testing. Moving into the second half of 2024, we will complete usability testing while at the same time ramping up our manufacturing capabilities. By the end of 2024, we intend to submit to FDA and other regulatory bodies in Europe, Japan, with the expectation of getting FDA clearance in mid 2025. We will move into a commercial pilot launch during the second half of 2025. Turning to the standalone ISU development at the bottom half of the slide. In collaboration with KARL STORZ, we intend to wrap up the design by end of 2023 and integration with the KARL STORZ vision platforms. During the first half of 2024, we intend to file regulatory submissions with expected approvals being received during the second half of 2024. We anticipate that we will begin commercialization by the end of that year. The LUNA timeline above will include a version of the ISU that will be integrated into the LUNA Digital Surgery Platform. While milestones will be less visible, we are hard at work continuing to develop the Asensus Cloud, and we are currently collecting and analyzing data from all the surgeries that utilize the ISU. We are using this data to enrich our Augmented Intelligence capabilities. We will continue to provide updates on these work streams as we move into the future. Hopefully, we have been able to convey to you today our excitement about all the great work being done at Asensus and our vision for the future. We believe that surgical outcomes can be improved by reducing surgical variability and democratizing access to next-generation technology. Performance-Guided Surgery is our vision for reimagining surgery. This will represent a true revolution in the evolution of surgery by taking surgery into the digital age. We are the right company to achieve this vision for Performance-Guided Surgery. We have the clinical, commercial, and regulatory experience necessary to design a complete digital surgery solution and get regulatory clearances and bring it to market. LUNA represents the next-generation surgical robotic system that will introduce unique features and will be economically responsible. The recently announced partnership with KARL STORZ will allow us to market and commercialize the ISU on a standalone basis, apart from its integration with our robotic systems. This is an exciting new revenue opportunity for Asensus, and we will also benefit from the significant volume of data that will be garnered from these incremental placements. This data will accelerate our ability to drive clinical learnings from our surgical datasets as well. As we have said consistently, a robot is not enough. A true digital surgery solution must be driven by best-in-class digital capabilities, including real-time intraoperative guidance and clinical insights driven by machine learning. We have been working behind the scenes on the design and development of our digital surgery solution for over four years. We believe that we have the right vision and the team to execute our vision and make it a reality. The next few years will be very exciting for Asensus. We look forward to sharing this journey with you. That concludes our presentation portion of today's program. I wanna thank everyone for their interest in Asensus and our vision for surgery. You heard a lot from our company today, and before we conclude, we want to bring up some actual users of our technology, surgeons. I would like to welcome to the stage the moderator of our surgeon panel, Dr. Ed Chekan, our company's Vice President in Medical Affairs, of Medical Affairs and Professional Education. Joining him up on stage are Dr. Amit Trivedi, chair of surgery at Pascack Valley Medical Center in New Jersey, and Professor Bernhard Krämer, deputy medical director of gynecology at Tübingen University Hospital in Germany. Ed will initially speak with the surgeons, and then soon after, Shameze Rampertab, our CFO, and I will be on stage to answer any questions soon after. Thank you, Anthony. Good afternoon, everyone. Welcome to the surgeon panel. My name is Ed Chekan, and I've been in this minimally invasive space in my surgical career for my entire career, and I'm excited to be here today to welcome this panel and to introduce them to you. First, please meet Dr. Amit Trivedi. Dr. Trivedi is the Chair of Surgery at Pascack Valley Medical Center in Westwood, New Jersey, where he specializes in bariatric and foregut surgery. As an early adopter of robotic surgery, he has years of extensive experience with both the Intuitive da Vinci system and the Asensus Senhance system. Since adopting the Senhance system in 2019, he has completed well over 400 cases and led the way as the most experienced ISU surgeon in the United States. Dr. Trivedi regularly presents at national meetings and is a strong advocate for the evolution of robotic technology in the operating room. Next, please meet Dr. Professor Bernhard Krämer. Dr. Krämer is the deputy medical director of OBGYN department at the University of Tübingen in Germany. He has over 25 years of experience in gynecological surgery with a focus on minimally invasive procedures. He has collaborated on research with many industry partners, including KARL STORZ. In addition to research on adhesion prophylaxis, his robotics projects concentrate on instrument development, team performance, ergonomics, and the workflow of MIS and robotic systems. Please join me in welcoming Dr. Trivedi and Professor Krämer. Thank you. Thank you. First let's start off with Dr. Trivedi. Let's get right to it. As you look back on your experience with Senhance, what were the key features and benefits that drove your decision and the hospital's decision to implement Senhance? Right. Great to be here, Ed. You know, a few years ago, I had the opportunity to become chair of a small community hospital in Northern New Jersey. I knew the future of the hospital involved robotic surgery. When I went to the CEO and asked for a robotic system, she basically said, "We cannot afford one." We're a brand-new hospital that recently opened up after being closed for several years. I said, "Well, that's not acceptable." I looked at the only other FDA-approved robotic system to this day, which was the Senhance system. I explained the reusable instruments, the ease of adoption, and she said, "Let's give it a try." We found that that was the right move for our hospital. The cost of acquisition, the cost of continued operations was a big factor. The learning curve was also a big factor. My hospital had never done robotic surgery before, but the fact that the Senhance was built on the foundations of laparoscopy made it easy for the team and the surgeons that would be helping in the OR and adopting the technology to really just start off very quickly. Our learning curve was ridiculously smooth. Now a robotic case with Senhance is just another case in our hospital. You know, I was very pleased a few months after we adopted that the CEO came up to me and said, "You know, we're already noticing a difference, that the reusable instruments that you're using, compared to disposable instruments for robotics are making a big difference in our bottom line." For a small hospital, that was, that was a big, big statement. Great. Thanks for your comments. Professor Krämer, how about you with Senhance? Well, our hospital in Germany is an expert center for minimally invasive gynae procedures with high numbers of patients, high volumes, and accordingly, our training is focused on laparoscopy rather than open procedures. We only do open procedures for extraordinary cases or for emergency cases. This is the historical background you need to know in order to understand. Right ... why we implemented the Senhance technology. We had the feeling that with Senhance, the transition from an expert laparoscopy center to the robotic world can be achieved easily, which is mainly due to the fact that we're already familiar with, you know, the key features such as the laparoscopic handpiece, instrumentation, energy, and the camera systems. Great. Collectively, we have a lot of experience up here with the Senhance System, and just over the last little bit here, we learned about the LUNA System and some of these new digital solutions. Dr. Trivedi, what are your thoughts on those developments? Yeah. I am very excited about the LUNA System. I think this represents a major paradigm shift in how we do surgery. Over the last 20 years, we've had great robotic systems, but what they've all been is telemanipulators. I do something, the robot refines my movements and reproduces them inside the patient. That was all great for the last 20 years. After hearing all of this, that era is over. The paradigm shift is the fact that for the first time, we'll have not only a cutting-edge robotic system with all the latest technology, but we will merge Augmented Intelligence that's cutting edge. I shouldn't even say cutting edge 'cause it's bleeding edge, 'cause some of the stuff we haven't even thought of yet. When you have that merger, I'll tell you why that is important. It's important because for the first time, I'll have real-time information on different surgical aspects, and that makes a big difference. This has the potential to create a co-pilot during surgery. We've never had that before. For all of us, if we get on a plane and the pilot comes on and says, "Well, the co-pilot called out sick today, and I'm just gonna take it from here," we'd be nervous about getting on that flight, but yet we do that for surgery almost every day across hospitals across the world. We don't have to do that anymore. If we had a co-pilot that watches over and helps and assists and gives real-time information, which is the key. Real time, I can use it during the operating room. That's a game changer. It'll help with outcomes. I wanna be able to measure that. It'll help with teaching, it'll help with safety, and it'll help with patient confidence. That's why I think this is a new way of doing surgery in the future. I'm very, very excited about it. Several things converging. Yeah ... new projects coming together that we're seeing it, like, you know, reality. It's astounding. How about for you, Dr. Krämer? I totally agree. I mean, for me, the most, you know, exciting thing is augmented reality and the digitization. You know, I can see how augmented reality will help us to define cutting lines, suture lines. Mm-hmm. to define critical difference, distances to adjacent structures. It will also help us to standardize training. I can see that will help us to decrease administrative issues, you know, such as, let's say, controlling the billing of our procedures as we can extract all the information from, you know, as we learned today, from the cloud and from digital solutions. So the bottom line is I would say that all this can happen during the procedure, not only preoperatively. Sure. Right. Right. Post-operative, but during the procedure, which is a big benefit for our daily practice, I would say. Yeah. Getting up to this point, we all recognize the benefits of the minimally invasive approaches over traditional open approaches. You know, as you see some of those types of benefits, maybe less complications or quicker procedures, how do you see Performance-Guided Surgery helping your patients? Do you see some of those same factors? Let's start with you, Dr. Trivedi. Is that some- Sure. -of the same factors? Yeah. I think Dr. Krämer had some great points. To this day, surgical variability is one of the leading causes of complications. That variability is what explains how care is different. We're in New York City here, and we're surrounded within a few miles of some of the greatest healthcare in the planet. We can't get that care in all parts of the United States even. If we can decrease that variability with real-time actionable information and tools, I think we can elevate the care that we provide to anywhere in the country, and I think that has a big implication. The other factor that's really important is what we just saw a little while ago with these no-fly zones. Mm. Not only does that have implications with safety and preventing injury to critical organs, but you can imagine as teaching, responsible surgeons, we can now actually encourage students to try to do different things knowing that there's a safety factor involved. I think that has implications in teaching as well. Very excited about that. Thank you. Professor Kramer, Performance-Guided Surgery. Again, the same for me, basically. You know, I think what the real message is, today that, you know, this system or Performance-Guided Surgery can help us to standardize our procedures, which leads to, you know, lower stress, lower physical and mental burden, and this ultimately leads to better patient outcomes. This is how... You asked me- Last a minute or so here, and I'll ask you one last question. I probably already know the answer, but I'll ask it anyway. What do you think your peers are gonna think about LUNA and these new digital solutions? How do you think this will resonate when you go back Monday, well, Tuesday morning, Wednesday morning, doing your next case? How will those folks see it? Yeah, I'll start off. you know, I think as surgeons across the nation and the world understand the implications of this, they'll realize that this is the way future surgery will be done. I don't think there's a surgeon out there that wouldn't want real-time information for a case. It could be as simple as measuring. you take an example of what we saw today. When we try to create a sleeve gastrectomy or a tumor margin, and we say, "Okay, we took about five centimeters. Right. Sometimes there's variation. If we can get the exact measurement and reproduce it every time, that's a different operation. We can measure results across the nation. We know what's working, what's not working. Yeah. Right. Make adjustments. That will take time. Yeah. -for surgeons to understand that. Once we deliver, once it's been delivered, I think, it'll adopt very quickly. How about in Europe or in Germany? Well, we've heard today that we are going to face a dramatic shortage of surgeons in the near future. Mm-hmm. We're not talking about the next 20, 30 years. We're talking about the next 5, 10, 15 years. Please forgive me, Dr. Trivedi, we're not talking about us, you know, the old guys. We need to attract the younger generation, you know, to work with new systems. We've heard today that they expect evolution, and I think the LUNA system is something that can bring this. You know, younger stuff, they are surrounded by digital technology in their private life basically all day, and I think for them it's highly attractive to work- Mm-hmm. with, such a system. They can adopt it very quickly. Sure. They can make it, you know, let's say their smartphone for surgery, may I say? I mean, that's, you know, a big word. Yeah. That's something, you know, that's, I suppose very attractive. That concludes our panel. Please thank the panelists here with me for being here today. Thank you for having us. Thank you. Thank you. Okay. Thank you. We will now move to Q&A. Does anybody... Mark? We're open console. We're just sitting like this in front of the surgeon console. The hand instruments and whatever fine movements we make will be reproduced in the patient for surgery, will be very easily adoptable. This concept of 3D vision makes depth perception a lot easier, and we heard today that it was glasses-less 3D. That, again, is another leap forward. We've not seen that before. We're excited to try that. I think even residents and folks in training will be eager to adopt and sit comfortably and do an operation with all the safety features that are there, the no-fly zones where we can identify structures, things like that. That would make a big difference in teaching as well. I think this will be the way we do surgery. Why stand up all for hours if need be when we can sit down and get real information right on our screen in a 3-D field? Mm-hmm. Big step forward. Yeah. I would add, it's, you know, dependent on how nicely the console and the handpieces are constructed. You know, we as surgeons, I mean, it's ever so nice to find, you know, fancy things in the OR, buttons to press, lights to show up. This is not what we need. We need, you know, a clear console. We need a nice handpiece. We need a digital solution, augmented reality during the procedure. We do not need, you know, the fancy stuff. I think from what we can see and from what we experienced, you know, as being surgical partners on the advisory board, this is going to be a very promising tool to actually go through a fast learning curve. Yeah. A second question, if I may. Just from the business side of things, you have had Senhance for a while now, and the adoption is improving every year as we see it. From here to move to LUNA, it's a game changer. At the same time, how do you evolve the commercialization from Senhance into LUNA? You know, do you see any issues in terms of if Do you need to stop Senhance via commercialization before you get started on LUNA, or how do you transfer folks from one to the other? Good question, R.K. Thank you for your questions. I think the current Senhance platform and the fact that we are in the field, there's a lot of learning from that. We understand what works in hospitals. We understand certain capital constraints. We know the challenges and the thing when I say we understand is every country and every region has a different dynamic. Those are the things that we learn from Senhance, and we're gonna continue to do that. The second piece that Senhance is bringing is the data. The more ISUs that we are gonna deploy within the Senhance ecosystem is going to continue, have a continuous flow of data. Now when the LUNA platform is ramped up, we will have all this data that's going to further inform the performance of the LUNA platform and the Augmented Intelligence engines. The manipulation part is going to change with LUNA compared to Senhance. The Augmented Intelligence piece is only going to get better and better the more data, and when we combine it with the LUNA platform, it's gonna be at a very different level than where it is today. I think there'll be a ramp up, ramp down, but I think the data and the ISU will be the bridge that connects the two over time. Thank you. Thanks. Hey, how's it going? This is, excuse me, Ross Osborn from Cantor Fitzgerald. Maybe starting off with the surgeons, first off, thanks for being here today and sharing your insights. I'd be curious to hear if you're seeing patients coming into your practices or hospitals asking for robotic surgery at this point, rather than lab. If not, you know, what do you think shifts from it being something surgeons like to offer then to something that patients would want to have? Sure. That's a great question. Through the 20-plus years of doing robotic surgery, we are now finally seeing patients coming in and asking for robotic surgery. It's more prevalent in the environment. People do their research in terms of who the surgeons are that do robotic surgery. A lot of patients also come knowing someone that's had robotic surgery. I do a lot of bariatric surgery, and for bariatrics, a good percentage of bariatric surgery across the nation has already converted to robotic surgery. Patients are on forums, they're on blogs, they talk to each other and they ask for robotic surgery. Once we explain that we do robotic surgery and they see how they feel afterwards, they tell other patients. The momentum is picking up even steam now. We're very excited about that. I don't know how it is in Europe, as much. Well, the uptake or the demand for robotic surgery for our patients is not very high at the moment. I mean, I'm a gynecologist, you know, so, patients do not necessarily ask for robotic procedures. The area where I'm located is a very, well, highly educated area in the south of Tübingen, you know, a small quaint university town. Whenever people, you know, hear about, I'm talking not about augmented reality, I'm talking about artificial intelligence, and I think we've heard today, I can't remember who it was, but we've heard that there is a difference. You know, the higher the education is, the more people think, "Oh, you know, someone's going to take over from surgeon." We are working on this process that the robot should be something to actually help us as surgeons and not to take over. I think that's, you know, a challenge for the future for us as surgeons to make our patients understand that the robot is helping us and not, you know, taking the procedure over. Mm-hmm. Great. Then maybe just one more, for Anthony or Shameze. Looking at your FDA approval that's expected for the ISU... Yeah. You mean ISU or the LUNA platform? The ISU. ISU. Okay. Because you brought up IDE. You know, we've had really good relationships with all the regulatory bodies, whether it's with FDA or Europe or in Japan. They are very aware of what we are doing and what we are working on. For the ISU, looking at a 2024 timeline, we become our predicate. It's the use case now becomes instead of a robotic use case, it'll be a standalone laparoscopy use case. We don't see significant challenges from ISU point of view, given that it is already approved in the current state, and it'll be a shift from robotic to a standalone laparoscopy component. Anthony, given the onerous pathway of FDA approval we've seen with J&J and Medtronic, what's the competitive advantage of your already cleared robot with Senhance? Will that help expedite or help navigate that pathway forward, especially for LUNA? I think it will, right? Two things. One, we become our own predicate. Second, we built LUNA with that intent, and we've had numerous conversations with the different regulators and we have a very clear pathway of what we need to do and by when. The timelines that we put up are considering those factors. One more question. The shifting centers of care out of the hospitals into the ASCs right now, especially in bariatric surgery. Right ...thinking about introducing new economic models there in order to facilitate that? I mean, Dustin talked about this, you know, we really have put a lot of effort on design for excellence in the design. Because in order to focus on ASCs, there are certain metrics, economic and performance that need to be met. We believe with the LUNA platform, we are very, very well positioned to be able to deliver the value and the performance in that type of a setting, given the whole reimbursement models and things like that. It is something of interest, and those were all the learnings that went into the design of the product, so that I mean, that you can't drive economic model after the fact. You need to work backwards to say, how do you build to deliver that economic model? We worked that equation backwards, and we knew what we had to, what envelope we had to work the design in order to deliver that solution. Shaymus Contorno, Oppenheimer, and for Suraj Kalia. Appreciate the information you've been able to give us on the Storz collaboration and whatnot. Can you give us a little more color when you maybe expect to generate revenue from that? Any updates we may receive, whatnot? Seamus, I think, you know, a few things. Like I said, over the next 90 days, we need to finalize our agreement. Once we do that, what we are looking at is trying to get the standalone product for a laparoscopic tower integrated with the KARL STORZ system, you know, get it into the hands of the regulators early part of 2024. Given that it is not a new product per se, it's the application of existing product in a different setting, we believe by middle of 2024, we'll be able to get the necessary approvals, because this solution does not require the camera component to be redesigned. It's a standalone camera that there are certain user interface elements that need to be discussed and agreed between the two companies in order to put that to market. I would think, you know, second half of 2024 is something that we would be a reasonable expectation to start getting the standalone ISU together with the lap tower or a OR1 kind of solution out in the market. Thank you. All right. I think that concludes our Q&A session. Really appreciate everybody joining us. We have some reception, some lunch, and also some demos that are in the next room that our team has put together. Some components of the LUNA system is actually in the room next door. If you'd like an overview, I'm happy to show you. Thank you very much for joining today, and we'll continue to keep you updated.